Literature DB >> 6179082

Carboxy terminus of polyoma middle-sized tumor antigen is required for attachment to membranes, associated protein kinase activities, and cell transformation.

G G Carmichael, B S Schaffhausen, D I Dorsky, D B Oliver, T L Benjamin.   

Abstract

We have constructed a transformation-defective polyoma virus mutant (Py 1387-T) that directs the synthesis of a normal small tumor antigen, a functional large tumor antigen, and a truncated (51,000-dalton) middle-sized tumor (mT) antigen that lacks 37 amino acids at its COOH terminus. The shortened mT polypeptide is missing the hydrophobic "tail" thought to be responsible for the anchorage of this protein into the plasma membrane and is in fact in cytosol fractions. This truncated mT polypeptide is inactive in an in vitro protein kinase assay and is altered in its phosphorylation in vivo. Mutant 1387-T differs from wild-type virus in having a T.A base pair instead of a C.G base at nucleotide position 1387. This change was introduced into viral DNA by using a synthetic undecanucleotide as a specific mutagen. Wild-type polyoma DNA was rendered single stranded by molecular cloning into coliphage M13. The oligonucleotide, which hybridizes with a mismatch at the site to be altered, was used to prime the synthesis of double-stranded closed circular DNA. Progeny recombinant phage were screened by DNA sequence analysis for the desired base change. The polyoma mutant was reconstructed from recombinant phage replicative form DNA molecules containing the mutation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179082      PMCID: PMC346465          DOI: 10.1073/pnas.79.11.3579

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Analysis of host range of nontransforming polyoma virus mutants.

Authors:  E Goldman; T L Benjamin
Journal:  Virology       Date:  1975-08       Impact factor: 3.616

2.  Host range selection of transformation-defective hr-t mutants of polyoma virus.

Authors:  R J Staneloni; M M Fluck; T L Benjamin
Journal:  Virology       Date:  1977-04       Impact factor: 3.616

3.  Host range mutants of polyoma virus.

Authors:  T L Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1970-09       Impact factor: 11.205

4.  Temperature-sensitive mutants of polyoma virus.

Authors:  G Di Mayorca; J Callender; G Marin; R Giordano
Journal:  Virology       Date:  1969-05       Impact factor: 3.616

5.  Complementation and transformation by temperature-sensitive mutants of polyoma virus.

Authors:  W Eckhart
Journal:  Virology       Date:  1969-05       Impact factor: 3.616

6.  Enchancement of the infectivity of simian virus 40 deoxyribonucleic acid with diethylaminoethyl-dextran.

Authors:  J H McCutchan; J S Pagano
Journal:  J Natl Cancer Inst       Date:  1968-08       Impact factor: 13.506

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  A system for mapping DNA sequences in the chromosomes of Drosophila melanogaster.

Authors:  P C Wensink; D J Finnegan; J E Donelson; D S Hogness
Journal:  Cell       Date:  1974-12       Impact factor: 41.582

9.  Localization of gene functions in polyoma virus DNA.

Authors:  J Feunteun; L Sompayrac; M Fluck; T Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

10.  Virus-specific proteins in the plasma membrane of cells lytically infected or transformed by pol-oma virus.

Authors:  Y Ito; J R Brocklehurst; R Dulbecco
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

View more
  76 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Interactions of polyomavirus middle T with the SH2 domains of the pp85 subunit of phosphatidylinositol-3-kinase.

Authors:  M Yoakim; W Hou; Y Liu; C L Carpenter; R Kapeller; B S Schaffhausen
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Functional asymmetry of the regions juxtaposed to the membrane-binding sequence of polyomavirus middle T antigen.

Authors:  J Dahl; U Thathamangalam; R Freund; T L Benjamin
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

4.  Expression of biologically active middle T antigen of polyoma virus from recombinant baculoviruses.

Authors:  J Forstová; N Krauzewicz; B E Griffin
Journal:  Nucleic Acids Res       Date:  1989-02-25       Impact factor: 16.971

5.  Interactions between polyomavirus medium T antigen and three cellular proteins of 88, 61, and 37 kilodaltons.

Authors:  T Grussenmeyer; A Carbone-Wiley; K H Scheidtmann; G Walter
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

Review 6.  Protein phosphatases and DNA tumor viruses: transformation through the back door?

Authors:  M C Mumby; G Walter
Journal:  Cell Regul       Date:  1991-08

7.  Polyomavirus tumor induction in mice: effects of polymorphisms of VP1 and large T antigen.

Authors:  R Freund; A Calderone; C J Dawe; T L Benjamin
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  A single-amino-acid substitution in polyomavirus VP1 correlates with plaque size and hemagglutination behavior.

Authors:  R Freund; R L Garcea; R Sahli; T L Benjamin
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Novel monoclonal antibodies that differentiate between the binding of pp60c-src or protein phosphatase 2A by polyomavirus middle T antigen.

Authors:  S M Dilworth; V P Horner
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Transformation by Polyomavirus Middle T Antigen Involves a Unique Bimodal Interaction with the Hippo Effector YAP.

Authors:  Cecile Rouleau; Arun T Pores Fernando; Justin H Hwang; Nathalie Faure; Tao Jiang; Elizabeth A White; Thomas M Roberts; Brian S Schaffhausen
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.